The Sabin Vaccine Institute (Sabin) inked a partnership with the Vaccine Research Center (VRC) National Institute of Allergy and Infectious Diseases (NIAID) to manufacture prototype ChAd3 vectored Ebola Sudan and Marburg vaccines to be used for further clinical evaluation and outbreak preparedness, and to potentially protect military, first responders, health care and laboratory workers, and other at-risk populations. Sabin will receive $5.3 million to manufacture Ebola Sudan and Marburg vaccines for the VRC.
Vaccines Desperately Needed
Life-saving vaccines against these viruses are overdue. From 2014-2016, an outbreak of the closely-related Ebola Zaire virus spread to 10 countries and took the lives of more than 11,000 people. The ongoing Ebola Zaire outbreak in the Democratic Republic of Congo has already claimed the lives of more than 2,200 people and was declared a Public Health Emergency of International Concern by the World Health Organization.
Existing Research Collaboration Agreement
This news comes as Sabin and NIAID VRC, under their existing Research Collaboration Agreement, will continue to work together to develop two individual vaccines against Ebola Sudan and Marburg viruses, building on VRC’s work to date.
The capital has been flowing as Sabin announced an initial award of $20.5 million with options for an additional $107 million from the Biomedical Advanced Research Development Authority (BARDA) to further support the two vaccine development programs just in September 2019.
Sabin Licenses Vaccines from GSK
This large BARDA contract followed an August agreement between Sabin and GlaxoSmithKline, under which Sabin exclusively licensed the technology for candidate vaccines against Ebola Zaire, Ebola Sudan, and Marburg viruses and acquired certain patent rights specific to these vaccines.
Vaccine Research Center
Clinical vaccine material is being manufactured for and funded by VRC under contract, for Good Manufacturing Practice (GMP)-grade Ebola Sudan and Marburg vaccines, through the Medical CBRN Defense Consortium—a consortium established for advanced development efforts to support the Department of Defense’s medical pharmaceutical and diagnostic objectives—at a level of $5.3 million with options up to $8.5 million.
Who is Sabin?
The Sabin Vaccine Institute, a non-profit organization founded in 1993, is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Sabin’s R&D strategy focuses on continuing the development of candidate vaccines that have demonstrated early scientific value and target disease, primarily impacting the world’s most vulnerable populations but have little commercial value. Sabin’s ChAd3 Ebola program is funded by the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services, as well as seed funding from Blavatnik Family Foundation and the David E.I. Pyott Foundation. In past years, Sabin received more than $110 million for vaccine R&D programs from public and philanthropic funding sources, including the Bill & Melinda Gates Foundation, European Commission, Dutch Ministry of Foreign Affairs, Global Health Innovative Technology Fund, and the Michelson Medical Research Foundation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policymakers, and public stakeholders to advance its vision of a future free from preventable diseases. Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live.